Business
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences: mwb online Health Care ConferenceDate: July 1, 2025Presentat
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences","length":70,"tagName":"p"},{"type":"text","content":"Halle (Saale) / Munich, Germany, June 27, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will present at the following investor conferences:","length":368,"tagName":"p"},{"type":"text","content":"mwb online Health Care ConferenceDate: July 1, 2025Presentation Time: 12:00 pm CEST Attendees: Frank Weber, CEO; Julia Neugebauer, COOVirtual conferenceLink to conference https://research-hub.de/events/registration/2025-07-01-12-00/VVY-NA","length":243,"tagName":"p"},{"type":"text","content":"H.C. Wainwright 4th Annual Kidney Virtual ConferenceDate: July 14, 2025 Presentation Time: 3:00 pm CEST / 9:00 am EDTAttendees: Frank Weber, CEO; Julia Neugebauer, COOVirtual conferenceLink to conference https://hcwevents.com/kidneyconference/","length":248,"tagName":"p"},{"type":"text","content":"###","length":3,"tagName":"p"},{"type":"text","content":"About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.&nbs...